Professor of Medicine, University Tex Houston
Oncology
Dr. Bonnie S. Glisson, MD
|
|
Give Review
Bonnie Glisson practices Oncology. She graduated from The Ohio State University College of Medicine. She has 4 awards "America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer" and "Super Doctor". Bonnie Glisson is a published doctor and has 62 publications published. The lastest was: 'MYB-fusions and other potential actionable targets in adenoid cystic carcinoma.' She is registered with Medicare.
Publications
- Outcomes for hypopharyngeal Carcinoma treated with organ-preservation therapy.
- Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal Carcinomas.
- Small cell lung Carcinoma: staging, imaging, and treatment considerations.
- A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma.
- Using multiplexed assays of oncogenic drivers in lung Cancers to select targeted drugs.
- A Phase II study of Gefitinib in Patients with Advanced Salivary Gland Cancers.
- Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β3-Src Pathway.
- The impact of radiographic retropharyngeal adenopathy in oropharyngeal Cancer.
- Outcomes and patterns of care of patients with locally advanced oropharyngeal Carcinoma treated in the early 21st century.
- Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx Cancer.
- Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA re...
- Patterns of Disease Recurrence Following Treatment of Oropharyngeal Cancer With Intensity Modulated Radiation Therapy.
- Epidermal growth factor receptor and K-Ras mutations and resistance of lung Cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.
- Phase II Study of Accelerated High-Dose Radiotherapy With Concurrent Chemotherapy for Patients With Limited Small-Cell Lung Cancer: Radiation Therapy Oncology Group Pr...
- An evolution in demographics, treatment, and outcomes of oropharyngeal Cancer at a major Cancer center: A staging system in need of repair.
- A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck.
- Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal Carcinoma (RTOG 0615): a phase 2 multi-institutional trial.
- Akt/mammalian target of rapamycin counteract the antitumor activities of cixutumumab an anti-insulin-like growth factor I receptor monoclonal antibody.
- Large-cell neuroendocrine Carcinoma: controversies in diagnosis and treatment.
- Novel strategies for the treatment of small-cell lung Carcinoma.
- Phase 2 study of dasatinib in the treatment of head and neck squamous cell Carcinoma.
- Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes an...
- Sorafenib in platinum-treated patients with extensive stage small cell lung Cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.
- Targeting an autocrine loop in small-cell lung Cancer: irrelevant target or ineffective drug?
- Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell Cancer.
- Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung Carcinoma.
- Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung Cancer as frontline and second-line therapy.
- Induction chemotherapy and cetuximab for locally advanced squamous cell Carcinoma of the head and neck: results from a phase II prospective trial.
- A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell Carcinoma of the head and neck.
- Durable long-term remission with chemotherapy alone for stage II to IV laryngeal Cancer.
- IMRT reirradiation of head and neck Cancer-disease control and morbidity outcomes.
- Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III...
- Outcomes after radiotherapy for basaloid squamous cell Carcinoma of the head and neck: a case-control study.
- Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung Cancer.
- Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell Cancer of the head and neck.
- Asian ethnicity as a predictor of response in patients with non-small-cell lung Cancer treated with gefitinib on an expanded access program.
- Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung Carcinoma.
- Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung Cancer.
- A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal Carcinoma.
- Neoadjuvant chemotherapy for squamous cell Carcinoma of the oral tongue in young adults: a case series.
- Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung Carcinoma.
- Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung Cancer: Report of Radiation Therapy Oncology...
- Sinonasal malignancies with Neuroendocrine differentiation: patterns of failure according to histologic phenotype.
- Phase I evaluation of docetaxel and topotecan for patients with advanced solid Tumors.
- Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid Tumors.
- Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung Cancer: report of a randomized comparative trial.
- Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck Carcinoma?
- A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal Carcinoma with early T status and advanced N status.
- Management of nonsinonasal neuroendocrine Carcinomas of the head and neck.
- Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus Carcinoma.
- Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung Cancer.
- Dose-dense therapy with a novel irinotecan regimen for small-cell lung Cancer.
- A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung Cancer.
- Recurrent small cell lung Cancer: update.
- The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung Carcinoma: potential for decreased toxicity an...
- Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell Carcinoma of the head and ...
- Direct correlation between FRA3B expression and cigarette smoking.
- The role of docetaxel in the management of squamous cell Cancer of the head and neck.
- Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell Carcinoma of the head and neck.
- Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin Cancer.
- MYB-fusions and other potential actionable targets in adenoid cystic Carcinoma.
Schools
Oh State Univ Coll Of Med and Pub Hlth
University Of Virginia
University Fla
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- Super Doctor
Education
-
University of Florida -
University of Virginia -
The Ohio State University College of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1073611950 | |
| NPPES Provider LastName | GLISSON | |
| NPPES Provider FirstName | BONNIE | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 230.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 30.0 | |
| Percent Opioid Claims | 13.04 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1073611950 |
| Last Name Of The Provider | GLISSON |
| First Name Of The Provider | BONNIE |
| View All |
Similar Doctors
|
Dr. Robert J. Amato, DO |
|
|
Dr. Francisco J. Esteva, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Mohammad Riaz, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Rachel L. Theriault, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James C. Yao, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Khaled W. Jabboury, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sao Jiralerspong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Teresa G. Hayes, MD |
|
|
Dr. Mathews L. George, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karin Hahn, MD
This Doctor is OpenDoctor Recommended.
|